Predominant symptoms in prostate cancer patients are erectile dysfunctions and urinary problems. As decreases of these functions can be attributed to disease and treatment but also to age-related decreases, we conducted a study on a German reference population measuring general quality of life (QoL) as well as prostate-specific symptoms. In cooperation with a German health insurance company, 3000 questionnaires were mailed to a randomly selected sample of men aged 45-75 years. Questionnaires used were the EORTC QLQ-C30 and a prostate-specific module (PSM). One thousand one hundred and fifty questionnaires were returned (response rate: 37.6%). QoL data from this reference population were compared to QoL data from a historical cohort study of prostate cancer patients following either prostatectomy or radiotherapy. In terms of general QoL, the reference population showed similar QoL scores as prostatectomy patients, but better scores than radiotherapy patients. On the PSM, the reference sample showed better overall QoL, but a surprisingly high extent of erectile dysfunction, urinary problems and psychic strain. Taking into account the sensitive topic of this study (sexuality and urinary problems), the response rate is more than satisfying. Older men in our randomly selected, population-based sample do not show perfect erectile and urinary function. These findings should be considered when interpreting QoL data of prostate cancer patients.
Introduction
Prostate cancer is one of the most common forms of cancer in males in Europe and in the USA. About 48 650 men in Germany are newly diagnosed with prostate cancer every year. 1 As the two major treatment options for patients with clinically localized prostate cancer (e.g. radical prostatectomy and radiotherapy) are considered to be comparable in terms of survival, 2 other therapyspecific health outcomes such as quality of life (QoL) may be important for treatment decisions. Furthermore, the great majority of patients receiving treatment for clinically localized prostate cancer ultimately die with, rather than of, their carcinoma. Therefore, the patients will have to live many years with the long-term effects of their treatment, 3 which may have adverse impact on the patients' QoL.
At present, a great number of questionnaires have been developed to measure general but also diseaseand/or treatment-specific QoL in patients with prostate cancer. In Europe, the most commonly used instrument for assessment of health-related QoL (HRQoL) in cancer patients is the EORTC QLQ-C30. 4 It is designed to be modular with the core questionnaire and additionally disease-and/or treatment-specific modules to measure disease-related symptoms or aspects of morbidity that are consequences of the supplied therapy or tumor site. Beginning in 1996, Kuechler and co-workers developed a prostate-specific module (PSM) in a process similar to the guidelines for the development of tumour-and therapy-specific modules established by the EORTC Study Group on QoL. 5 The prostate cancer module consists of 36 items addressing therapy and prostate cancer-specific issues such as change of sexual problems, urinary problems or treatment strain leading to the scales 'urinary problems', 'incontinence', 'erectile dysfunction', 'sexual problems', 'problems with partner', 'pain', 'heat', 'nutrition' and 'psychic strain'. 6 Predominant symptoms in prostate cancer patients are erectile dysfunction and urinary problems. Within Europe and especially Germany, there is an ongoing debate on what symptoms are prostate cancer associated and what amount of symptoms is normal in men with increasing age. As decreases of these functions can be attributed to disease and treatment but might also be age related, we conducted a study on a German reference population measuring as well general QoL as prostatespecific symptoms using the EORTC QLQ-C30 and the PSM. A few studies have been performed to obtain QoL data from reference populations, 7 but this is the first trial measuring disease-specific QoL in a German reference population targeting prostate-specific QoL. The data from this study can be used as comparison group in studies with older men treated for prostate cancer.
Patients and methods

Subjects
A population-based sample of N ¼ 3000 men aged 45-75 years (selected according to prostate cancer incidence) was randomly selected from the computer records of a German general health insurance company ('Sancura BKK'). As we intended to investigate health-related QoL in the general population, no medical inclusion or exclusion criteria were defined. A letter of introduction was mailed to all selected subjects from the health insurance company. Two weeks later, each patient was mailed the questionnaires together with a pre-stamped return envelope. In order to provide a high level of anonymity, the mailing was carried out by a neutral private company. All patients who returned their questionnaires within 4 weeks were included in the analysis; a non-responder analysis was not possible due to strict anonymization.
As a comparison group, five historic cohorts of prostate cancer patients completing the same set of questionnaires were used. This sample consists of N ¼ 950 patients following either radical prostatectomy or radiation therapy. 6 The patients following radiotherapy were a little older than the prostatectomy patients; furthermore, they tend to have higher tumor stages. Therefore, in order to reduce this bias and to keep the groups (radiotherapy vs prostatectomy) comparable, the sample was restricted solely to a subsample of N ¼ 375 patients with low or intermediate risk according to international classification standards. 8 QoL assessment was restricted up to 2 years after primary treatment. Altogether, 39 patients following radiotherapy and 436 patients following prostatectomy were included in the statistical analysis.
Statistical analysis
The scoring of the EORTC QLQ-C30 core questionnaire and the PSM was performed according to the EORTC QLQ-C30 Scoring Manual: 5 scales were calculated when at least half of the items were completed by the patients. Internal consistency of the PSM was assessed by calculating Cronbach's alpha. Results are presented as total numbers (%) or mean7s.d. All distribution and frequencies were compared by w 2 test. QoL analyses were performed parametrically using unpaired t-tests and analyses of variance.
A P-value less than 0.05 was considered to be statistically significant (corrected for multiple tests), whereas a mean difference of 10 points and more on the QoL scales represents a clinically significant/relevant difference. 9 
Instrumentation
HRQoL was assessed using the EORTC QLQ-C30 Core Questionnaire (Version 2.0) and the PSM. The EORTC QLQ-C30 is a cancer specific 30-item questionnaire. 4 It includes five functional scales (physical, role, cognitive, emotional and social), four symptom scales (fatigue, pain, nausea and vomiting) and a global health scale. There are also a number of single items addressing additional symptoms commonly reported by cancer patients (dyspnea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial effect of the disease. In the QLQ-C30, all items have response categories with four levels, from 'not at all' to 'very much', except the two items of the global health scale (overall physical condition and for overall QoL), that use seven-point items ranging from 'very poor' to 'excellent'. High scale scores present a high response level, with high functional scale scores representing high/healthy levels of functioning, and high scores for symptoms scales/items representing high levels of symptomatology/problems. 5 The PSM consists of 36 items addressing therapy and prostate cancer-specific issues such as change of sexual problems, urinary problems or treatment strain leading to the theoretical scales 'sexuality', 'pain', 'micturition', 'partnership', 'heat', 'general symptoms' and 'incontinence'. The PSM was used in several (mainly historical cohort) studies in Germany and has been psychometrically tested using data from an empirical meta-analysis. 6 The PSM scales are scored according to the EORTC QLQ-C30 symptom scales ranging from 0 to 100, with high values representing a high level of symptomatology/ poor QoL.
Results
Sample description
The mailing was conducted from 1st of March until 15th of April 2004. Within this time frame, 1150 out of the 3000 mailed questionnaires were returned by the patients (response rate: 38.3%). Mean age of all respondents was 56.8 years (s.d. 7.7). Sociodemographic data are displayed in Table 1 .
Even though the respondents in this sample are somewhat younger than 'the average prostate cancer patient', these data indicate that this sample of male 'non-patients' can be assumed to be comparable to prostate cancer patients.
Psychometric properties of the PSM
As this disease-specific module was used the first time in a 'healthy' population, the first step of analysis was an evaluation of the module's psychometric properties. The PSM indicates good to sufficient internal consistency with a total Cronbach's alpha of 0.74. For the module scales, Cronbach's alpha ranges from 0.49 to 0.94. Only the scales '(prostate-specific) pain' and 'nutrition' show poor internal consistency (Cronbach's alphao0.7);
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As the psychometric properties do not differ significantly from the reliability coefficients reported in the original validation study, we therefore assume the module can be used for assessment of HRQoL in men without prostate cancer too.
QoL data
The EORTC QLQ-C30 Functional Scales are shown in Figure 1 . Overall, subjects performed well on all functional scales. Apart from 'emotional functioning', all functional scales decrease with increasing age. Especially on the scale 'physical functioning', a remarkable age-related deterioration was found. Young patients (aged 45-50 years) reported statistically and clinically significant better QoL than older patients (aged 71-75 years), with a mean difference of at least 10 points on all EORTC QLQ-C30 Functional Scales but 'emotional functioning'. Figure 2 shows the EORTC QLQ-C30 Symptom Scales. With increasing age, the symptom levels for 'fatigue', 'pain', 'dyspnea', 'insomnia' and 'financial difficulties' increase too. Especially men aged 71-75 years show high levels of symptomatology. For 'nausea/vomiting', 'appetite loss' and 'diarrhea', no clear age-related trend was found. Figure 3 shows that similar to the findings for the EORTC QLQ-C30 Symptom Scales, increasing age also is associated with increasing levels of symptomatology on the PSM Scales. On all PSM Scales, patients aged 71-75 years show a significantly poorer QoL than younger patients. The mean values for 'erectile dysfunction', 'sexual problems' and 'psychic strain' increase remarkably with increasing age.
Men aged 45-50 years and men aged 51-55 years show similar erectile dysfunction scores. The mean difference on the erectile dysfunction scales between young (aged 45-50) and old men (aged 71-75) is about 30 points, which is not only statistically but also clinically of high significance (Figure 4 ).
More than one-third of all respondents report some degree of urinary dysfunction; 42.3% suffer from postvoid dribbling. Like on the other scales, all urinary symptoms increase with increasing age, that is, younger patients report better urinary function.
When compared to prostate cancer patients, the healthy reference population shows similar QoL scores as prostatectomy patients on the EORTC QLQ-C30 Functional and Symptom Scales. Only on the 'social functioning' scale the reference population scored significantly better than prostatectomy patients. Comparing the reference population to radiotherapy patients, we found statistically and clinically significant differences for 'physical functioning', 'role functioning', 'social functioning', 'pain' and 'diarrhea', with radiotherapy patients showing poorer QoL ( Figure 5 ). 
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On the PSM, we found similar QoL scores for prostatectomy patients and the (healthy) reference population in terms of 'urinary problems', '(prostatespecific) pain', 'nutrition' and 'psychic strain'. Even though the healthy reference population does not reach the level of prostate cancer patients (prostatectomy as well as radiotherapy patients), they show remarkably high scores for 'erectile dysfunction' and 'sexual problems' (Figure 6 ). In summary, prostate cancer patients differ clinically significant (Owing to the large sample size, almost all differences are statistically significant, but certainly not clinically relevant.) from the reference group of 'nonpatients' in four out of eight scales from the PSM.
As this study was designed to provide reference values for QoL assessment in prostate cancer patients, the mean scores and s.d. for all QoL scales are displayed in Table 3 .
Discussion
In this cross-sectional study, we have analyzed HRQoL in a German reference population. The questionnaires 
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were mailed to a randomly selected sample of N ¼ 3000 male insurants of a German health insurance company. Taking into account not only the sensitive topic but also the facts that the questionnaire is comparatively long and -due to strict anonymization -the use of incentives was not possible, a response rate of 38.3% is really satisfying. In a comparable study of older men without prostate cancer in the USA, where cash incentives and telephone reminders were used, a response rate of 44.8% was achieved. 10 The questionnaires analyzed for this paper were the EORTC QLQ-C30 core questionnaire 4 and a newly validated PSM developed by Kü chler et al. 6 A psychometric analysis of this healthy sample showed that the PSM showed highly satisfactory internal consistency with a mean Cronbach's alpha of 0.73. We therefore assume that this disease-specific instrument can be used for the assessment of HRQoL in this German general population.
In terms of general QoL (QLQ-C30), the reference population showed similar QoL scores as prostatectomy patients, but better scores than radiotherapy patients. On the PSM, the reference sample showed better QoL, but a high extent of erectile dysfunction, urinary problems and psychic strain. Many studies compared HRQoL outcomes after between treatments and at various times of assessment. The findings of these studies are heterogeneous and many of them have methodological limitations. One possible reason for the differences between prostatectomy and radiotherapy patients in this study could be that the radiotherapy patients are a generally more 'unhealthy' subset of patients, that is, that patients in a poorer general condition are more likely to receive radiotherapy. Therefore, we tried to minimize this bias by restricting the sample solely to patients with low to intermediate risk.
Not only the EORTC QLQ-C30 functional and symptom scales but also the scales from the PSM showed significant dependencies on age. On all EORTC QLQ-C30 Figure 4 Urinary problems of 'non-patients', all age groups.
Functional Scales, but 'emotional functioning' and 'cognitive functioning', a remarkable age-related decrease was found. For the EORTC QLQ-C30 Symptom Scales, we found that increasing age is associated with increasing levels of symptomatology. On the PSM scales, it was shown that increasing age also corresponds with higher levels of prostate-specific symptoms. For most PSM scales, a linear relationship between age and scale score was found. The increase of symptoms is most pronounced in the oldest age group. Similar findings were reported for the EORTC QLQ-C30 scales by Hjermstad et al. 11 and Schwarz and Hinz. 7 This underlines the necessity to account for age differences when populations with different age distributions are compared. However, it should be kept in mind that these data were obtained from a cross-sectional design and not from a prospective sample. Another limitation of this study is the respondents' age. With a mean age of 57 years, this sample is clearly younger than the median age at diagnosis of prostate cancer patients (B70 years). As the participants of this study were randomly selected from the records of a health insurance company, this fact indicates a response bias (younger patients are more likely to answer the questionnaires than older ones). It would have been interesting to get more information about this bias, but due to strict anonymization, a non- Symptoms of prostate cancer in a German general population B Bestmann et al responder analysis was not feasible. Nevertheless, as the data of this study is not analyzed and presented as a whole, but in a age-stratified way, this reference data allow future comparisons with different samples of prostate cancer patients obtained from clinical studies.
Comparing the reference sample to the historic cohort of prostate cancer patients on the EORTC QLQ-C30 scales, it was shown that the healthy sample showed similar QoL scores as prostatectomy patients, but significantly better QoL than radiotherapy patients on the PSM; the reference sample showed better QoL than prostate cancer patients (prostatectomy patients as well as radiotherapy patients), but also a remarkably high degree of 'erectile dysfunction' and 'sexual problems'. Interpreting these differences, it has to be kept in mind that the reference population studied in this paper is no completely healthy but rather a 'normal' sample. Patients with a history of prostate or other sites of cancer were not excluded from this survey. We assume that the incidence rate for prostate cancer in this randomly selected sample is comparable to the incidence rate in Germany in general.
Conclusions
Comparisons with reference populations facilitate to interpret the significance of differences in QoL scores of different patient groups (e.g. patients with high and low tumor stage) and score changes over time.
The male 'non-patients' in our randomly selected, population-based sample do not show perfect erectile and urinary function. The data showed decreases in sexual functions not only for prostate cancer patients but also to some extent for the age-matched reference population. The increase of symptoms and decreases of sexual and urinary function in prostate cancer patients should therefore not only be attributed to radical treatment for prostate cancer but also to the normal aging process as well. These findings should be kept in mind when interpreting QoL data of prostate cancer patients. Symptoms of prostate cancer in a German general population B Bestmann et al
